Inhibrx Biosciences Ratios (2023-2025) | INBX

Ratios Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
EBT Margin (Quarter) -156,823.33%-43,518.49%-5,628.76%1,858,013.00%-47,865.00%-2,204.00%
EBIT Margin (Quarter) -137,796.67%-38,510.08%-5,403.24%-160,898.00%-49,928.00%-2,106.85%
EBITDA Margin (Quarter) -137,796.67%-38,510.08%-5,403.24%-160,898.00%-49,928.00%-2,106.85%
Operating Margin (Quarter) -137,796.67%-38,510.08%-5,403.24%-160,898.00%-49,928.00%-2,106.85%
Net Margin (Quarter) -156,840.00%-43,520.17%-5,628.52%1,858,011.00%-47,865.00%-2,204.15%
FCF Margin (Quarter) -46,265.55%-3,688.07%-57,258.00%-43,736.00%-2,305.69%
Efficiency
Assets Average (Quarter) 240.49M201.66M211.70M227.38M194.79M161.97M
Equity Average (Quarter) 52.39M86.55M27.54M115.47M198.92M156.03M114.01M81.50M52.69M22.41M
Invested Capital (Quarter) -24.81M129.59M43.50M11.57M219.37M178.47M133.58M193.10M167.84M136.75M108.55M
Asset Utilization Ratio (Quarter) 0.010.010.010.010.01
Leverage & Solvency
Interest Coverage Ratio (Quarter) -5.23-5.62-10.74-9.08-30.01-15.95-8.72-10.63-9.71
Debt to Equity (Quarter) 4.761.041.452.7112.58
Debt Ratio (Quarter) 0.670.410.470.560.69
Equity Ratio (Quarter) 0.140.850.800.740.390.320.210.05
Times Interest Earned (Quarter) -5.23-5.62-10.74-9.08-30.01-15.95-8.72-10.63-9.71
Valuation
Enterprise Value (Quarter) -277.92M-226.90M-196.33M-152.60M-216.52M-186.57M-153.10M-124.22M
Return Ratios
Return on Sales (Quarter) -15.68%-4.35%-0.56%185.80%8.87%-4.79%-0.22%-1.11%-1.00%
Return on Capital Employed (Quarter) -188.30%-205.95%-178.82%-88.63%-96.99%-105.34%
Return on Invested Capital (Quarter) -0.09%-0.02%-0.02%-0.02%-0.01%-0.01%-0.01%
Return on Assets (Quarter) 0.07%0.08%0.08%-0.01%-0.01%-0.01%
Return on Equity (Quarter) -0.10%0.14%0.08%0.11%0.15%-0.02%-0.03%-0.06%